Why Metrics Matter in Thyroid Eye Disease

Importance Advances in the understanding of the pathophysiology of thyroid eye disease (TED) provide an opportunity to use novel, targeted therapeutic agents. However, our capacity to assess the efficacy and indications for the new agents is potentially limited by the clinical metrics used in recent research trials, which fail to adequately capture the clinical complexity and diversity of TED. Objectives To review the features of TED that make it atypical among autoimmune diseases, review the limitations of the currently available metrics, and introduce the Innovate TED Initiative to develop new outcome metrics. Conclusions and Relevance To best evaluate and use potential new therapeutic agents for TED, physicians with expertise in the field perceive the need for a novel set of metrics. The outlined Innovate TED Initiative can, through the design and execution of prospective validation studies, develop the requisite metrics for the mutual benefit of physicians, regulatory bodies, the pharmaceutical industry, and patients with TED.

Authors

Institutions

Publication Details

Journal
JAMA Ophthalmology
Published
2026-09-10
DOI
https://doi.org/10.1001/jamaophthalmol.2026.3823
Primary Topic
Ophthalmology and Eye Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Why Metrics Matter in Thyroid Eye Disease

Peter J. Dolman, A. Augusto Cruz, Timothy J. Sullivan, Louise A. Mawn et al.
JAMA Ophthalmology
Ophthalmology and Eye Disorders
article

Why Metrics Matter in Thyroid Eye Disease

Peter J. Dolman, A. Augusto Cruz, Timothy J. Sullivan, Louise A. Mawn, Chrysoula Dosiou, Michael Kazim, Daniel B. Rootman, Andrea L. Kossler, Marius N. Stan, Naykky Singh Ospina, Mario Salvi, Don Kikkawa, Anja Eckstein, Lelio Baldeshi, Petros Perros, Sara T. Wester
article en

Abstract

Importance Advances in the understanding of the pathophysiology of thyroid eye disease (TED) provide an opportunity to use novel, targeted therapeutic agents. However, our capacity to assess the efficacy and indications for the new agents is potentially limited by the clinical metrics used in recent research trials, which fail to adequately capture the clinical complexity and diversity of TED. Objectives To review the features of TED that make it atypical among autoimmune diseases, review the limitations of the currently available metrics, and introduce the Innovate TED Initiative to develop new outcome metrics. Conclusions and Relevance To best evaluate and use potential new therapeutic agents for TED, physicians with expertise in the field perceive the need for a novel set of metrics. The outlined Innovate TED Initiative can, through the design and execution of prospective validation studies, develop the requisite metrics for the mutual benefit of physicians, regulatory bodies, the pharmaceutical industry, and patients with TED.

JAMA Ophthalmology
Cliniques Universitaires Saint-Luc (BE), Mayo Clinic (US), University of British Columbia (CA), University of Miami (US), The University of Queensland (AU), Universidade de São Paulo (BR), Royal Brisbane and Women's Hospital (AU), UC San Diego Health System (US), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Florida (US), University of California San Diego (US), Doheny Eye Institute (US), Smith-Kettlewell Eye Research Institute (US), University of Duisburg-Essen (DE), Columbia University (US), Newcastle University (GB), Vanderbilt University Medical Center (US), UCLouvain (BE), Stanford University (US)
Partnerships for the goals
Openalex Percentile: Top 11%
Ophthalmology and Eye Disorders
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.